Actavis has issued a nationwide recall of Digitek (digoxin tablets) due to the possibility that tablets with double-thickness, containing twice the approved level of active ingredient, may have been commercially released. The existence of double strength tablets poses a risk of digitalis toxicity in patients with renal failure. Digitalis toxicity can cause nausea, vomiting, dizziness, low blood pressure, cardiac instability, bradycardia, and possible fatality. Several reports of illness and injuries have been received.
The recalled Digitek tablets include all lots distributed by Mylan under the “Bertek” label and UDL Laboratories under the “UDL” label.
For more information call (888) 276-6166 or visit www.actavis.us.